Preclinical studies demonstrate that EZH2 inhibitors, tazemetostat and valemetostat, upregulate antigen HLA class I/II presentation machinery, OX40L, CD80 co-stimulatory ligands, and T cell-attracting chemokines, CXCL9 and CXCL10 in tumor cells. This evidence concerns the gene CD80 and neoplasm.